Novartis puts pressure on Germany's retrospective AMNOG reviews
This article was originally published in Scrip
Executive Summary
Companies sweating over whether their older products will be called up for retrospective review under Germany's tough AMNOG health technology appraisal process are holding their breath. A court has temporarily halted the back assessment of gliptins already on the market and is deciding whether to uphold a complaint about the process from Novartis. A ruling in favor of Novartis could delay more retrospective assessments, or even foil them altogether.
You may also be interested in...
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.
New HTA Evidence Guidelines In EU Could Spell Trouble For Advanced Therapy Companies
New guidelines that cast doubt over use of single-arm and non-randomized studies are “discouraging” for rare disease patients and the advanced therapy sector, says ARM, the Alliance for Regenerative Medicines.
Germany Courts Clinical Trials With Regulator Reshuffle & New Federal Ethics Committee
Plans to rejig two regulators’ roles and streamline the ethics committee system have drawn some criticism.